Cephalostatin 1, OSW-1, ritterazine B and schweinfurthin A are natural products that potently, and in some cases selectively, inhibit the growth of cultured human cancer cell lines. The cellular targets of these small molecules have yet to be identified. We have discovered that these molecules target oxysterol binding protein (OSBP) and its closest paralog, OSBP-related protein 4L (ORP4L)-proteins not known to be involved in cancer cell survival. OSBP and the ORPs constitute an evolutionarily conserved protein superfamily, members of which have been implicated in signal transduction, lipid transport and lipid metabolism. The functions of OSBP and the ORPs, however, remain largely enigmatic. Based on our findings, we have named the aforementioned natural products ORPphilins. Here we used ORPphilins to reveal new cellular activities of OSBP. The ORPphilins are powerful probes of OSBP and ORP4L that will be useful in uncovering their cellular functions and their roles in human diseases.
values of 0.60-0.83 (ref. 4) , respectively. The stellettin family of natural products is linked to cephalostatin 1, OSW-1, ritterazine B and schweinfurthin A through a pattern of cytotoxicity shared with schweinfurthin A (r = 0.75 for schweinfurthin A and stellettin A 4 ). The highly correlative cancer cell line sensitivities of these four compounds and stellettin E suggest that all five molecules share a cellular target or affect the same cellular pathway(s) 9 . Furthermore, the shared cell line sensitivity pattern of these compounds against the NCI-60 is unique compared to the pattern of the other ~40,000 growth-inhibitory small molecules evaluated, indicating that the five compounds have new cellular target(s) 11 . However, the cellular target(s) of these compounds has not been identified.
The five compounds each have interesting cellular activities. Cephalostatin 1 induces apoptosis through an atypical mechanism 12, 13 . OSW-1 is 30-to 150-fold more cytotoxic toward glioblastoma and leukemia cells compared to nontransformed astrocytes and lymphocytes, respectively 8 . Schweinfurthin A and stellettin E selectively inhibit growth of tumor cells deficient in NF-1 (ref. 14) or p21 Cip/Waf1 (also known as CDKN1A, and hereafter referred to as p21) 5 , respectively. Repression of p21 expression 15 and loss of NF-1 (ref. 14) is important for the development of some tumors. Therefore, small molecules that selectively inhibit the growth of tumor cells with these genetic alterations could be tumorspecific therapeutics.
Herein we reveal that OSBP and ORP4L are targets of cephalostatin 1, OSW-1, ritterazine B and schweinfurthin A. OSBP and ORP4L (also known as OSBP2 or HLM) belong to a 16-member protein superfamily 16, 17 , OSBP and the ORPs, that has been implicated in lipid metabolism 18, 19 , signaling 20, 21 , vesicular traffic 22 and nonvesicular sterol transport 23, 24 . Although OSBP was the first protein discovered to bind endogenous oxysterols 25, 26 , its function and that of its ORP paralogs remains largely unclear. Because these four natural products all target OSBP and ORP4L, we have named this family of compounds ORPphilins (ORP here stands for `OSBP and related proteins'). By uncovering the cellular targets of the ORPphilins, we have revealed that OSBP and ORP4L are involved in cancer cell survival. This discovery provides another link between cancer cell proliferation and lipid processing 27 .
RESULTS

OSBP and ORP4L are receptors of ORPphilins
We accessed cephalostatin 1 using our total synthesis procedure 28 , and we used OSW-1, ritterazine B and schweinfurthins A and B isolated from natural sources. We did not have access to stellettin E, and our small supply of ritterazine B limited its use in our experiments. As similar NCI-60 cytotoxicity profiles are only suggestive of a shared mechanism of action between compounds, we sought additional experimental support that the ORPphilins and stellettin E form a new class of mechanistically related anti-proliferative agents. Stellettin E is 117 times more growth-inhibitory to HCT-116 CDKN1A −/− (p21 −/− ) cells than to HCT-116 wild-type cells 5 . We determined that the growth-inhibitory activities of the ORPphilins were also significantly enhanced in HCT-116 p21 −/− cells versus HCT-116 wild-type cells (Fig. 2a) . Many of the other antiproliferative small molecules we tested did not show this p21 −/− selectivity (Fig. 2a) . The p21 −/− selectivity was the first evidence beyond the NCI-60 COMPARE analysis that cephalostatin 1, OSW-1, ritterazine B, schweinfurthin A and stellettin E were mechanistically related. In addition, the p21 −/− selectivity was a defining feature for this class of compounds, which we used to identify ORPphilin analogs that shared the same mechanism of action.
We used affinity purification to identify putative targets of the ORPphilins. Because OSW-1 is the most abundant of the natural products, we prepared several OSW-1 analogs (6-10, Fig. 1 ), and we subsequently determined their potencies and p21 −/− selectivities. We discovered that an allyloxycarbonyl (alloc)-protected amine (6), prepared through carbamate formation at the C3-hydroxyl of the xylosyl saccharide, maintained the antiproliferative potency of OSW-1 (Supplementary Results, Supplementary Fig. 1a ) and, critically, also showed p21 −/− selectivity commensurate with that of OSW-1 (Fig. 2a) .
Amine 6 was then deprotected and covalently linked to Sepharose resin to prepare OSW-1 affinity reagent (OAR) (Fig. 1) . Affinity chromatography of HeLa-S3 cell lysate with OAR followed by protein gel electrophoresis afforded a highly enriched band at ~90 kDa (Fig.  2b) . Critically, pretreatment of the HeLa-S3 lysate with 10 μM of OSW-1 competed away this band (Fig. 2b) , indicating that this protein specifically bound OSW-1. Analysis of the full gel lane by iTRAQ-based quantitative mass spectrometry identified this band as OSBP. Among the 121 identified proteins enriched in the OAR pulldown, OSBP and its paralog ORP4L showed the largest extent of competition by soluble OSW-1 (Fig. 2c) . Expression from two alternative transcription start sites produces two ORP4 isoforms: a long version (ORP4L) of 916 amino acids and a short version (ORP4S) of 461 amino acids. The peptide coverage in our iTRAQ experiment contains ORP4L-specific sequences, but we cannot exclude the possibility that ORP4S or another as-yet-unidentified ORP4 isoform was also pulled down. Additionally, vesicle-associated membrane protein-associated protein A (VAP-A), which is known to interact with both OSBP 29 and ORP4L 30 , was significantly enriched and competed away by OSW-1 pretreatment. OSBP and ORP4L are believed to physically interact 31 . Therefore, any of these three proteins-OSBP, ORP4L or VAP-Acould have been the direct binding partner of the OAR, with the other two proteins being copurified. However, as OSBP and ORP4L are high-affinity receptors of oxysterols 31 , and OSW-1 comprises an oxysterol moiety, we chose to investigate OSBP and ORP4L as putative targets of the ORPphilins.
To determine whether the ORPphilins directly bind OSBP or ORP4L, we performed competition-binding assays with OSBP-Myc-His and ORP4L-Myc-His using [ 3 H]25-hydroxycholesterol (25-OHC, Supplementary Fig. 2 ), a high-affinity ligand of both proteins (OSBP K D = 32 ± 14 nM; ORP4L K D = 54 ± 23 nM, Supplementary Fig. 1b) . We found that cephalostatin 1, OSW-1, ritterazine B and schweinfurthin A each bound OSBP-Myc-His (K i = 39 ± 10 nM, 26 ± 9 nM, 28 ± 4 nM and 68 ± 23 nM, respectively) and ORP4L-Myc-His (K i = 78 ± 15 nM, 54 ± 11 nM, >360 nM and 2,600 ± 570 nM, respectively) (Fig. 2d,e) . Schweinfurthin A was an outlier compared to the other ORPphilins in that its affinity for ORP4L was considerably lower (by a factor of ~40) than its affinity for OSBP.
OSBP and ORP4L levels affect ORPphilin activity
We performed shRNA knockdown of OSBP expression and then measured its effect on the growth-inhibitory activity of cephalostatin 1, OSW-1 and schweinfurthin A. Reduction of OSBP levels by 85% (Fig. 3a) did not affect HCT-116 p21 −/− cell growth ( Supplementary  Fig. 3 ), but OSBP shRNA knockdown sensitized cells to cephalostatin 1, OSW-1 and schweinfurthin A by four-, six-and nine-fold, respectively (Fig. 3b) . Sensitivity to taxol was not affected by shRNA knockdown of OSBP, revealing that OSBP protein levels do not nonspecifically enhance the activity of cytotoxic small molecules. Similar results were obtained in HeLa cells (Supplementary Fig. 5 ). Unfortunately, antibodies to ORP4L, either from commercial sources or developed in our lab, did not recognize endogenous levels of ORP4L in various cell lines, which prohibited conducting ORP4L knockdown experiments. However, we performed both OSBP and ORP4L overexpression and cytotoxicity experiments (Fig. 3c ). OSBP and ORP4L overexpression each desensitized HeLa cells to the antiproliferative activity of cephalostatin 1, OSW-1 or schweinfurthin A by a factor of approximately 2-5 (Fig. 3d) . Taxol-induced growth inhibition was not affected by overexpression of either OSBP-Myc-His or ORP4L-Myc-His (Fig. 3d) .
Correlation of OSBP and ORP4L binding to ORPphilin activity
If the antiproliferative activity of the ORPphilins is mediated by OSBP, ORP4L or both, a positive correlation between their affinity for OSBP and ORP4L and their antiproliferative activity should exist. Indeed, plotting the OSBP K i values versus the HCT-116 GI 50 values of the ORPphilins and four OSW-1 analogs (6-9) revealed a strong positive correlation (r = 0.9644) (Fig. 3e) . The same analysis with the ORP4L K i values also revealed a strong positive correlation (r = 0.9069) but only when schweinfurthin A was excluded (Fig. 3f) . We obtained similar SAR correlation results for both OSBP and ORP4L in the A549 and HCT-116 p21 −/− cell lines (Supplementary Fig. 6 ). Further supporting this correlation, analog 10, which bears a tert-butyldimethylsilyl group on the C3 carbinol ( Fig. 1) , was approximately 1,400-fold less cytotoxic in HCT-116 cells (GI 50 = 2,300 nM), 700-fold less cytotoxic in A549 cells and 2,100-fold less cytotoxic in HCT-116 p21 −/− cells compared to OSW-1 ( Supplementary Fig. 1a) . Notably, analog 10 also did not compete with [ 3 H]25-OHC for binding to OSBP or ORP4L (Supplementary Fig. 1c ).
25-Hydroxycholesterol suppresses ORPphilin activity
25-OHC is not cytotoxic at concentrations up to 10 μM in most cell lines. ORPphilins competed with 25-OHC for binding to OSBP and ORP4L with K i values similar to the 25-OHC K D (Fig. 2d,e) . Therefore, in cells, administration of sublethal doses of 25-OHC with the ORPphilins should inhibit binding of the ORPphilins to OSBP and ORP4L, thereby desensitizing cells to the cytotoxic effects of the ORPphilins. We found that addition of 25-OHC caused a dose-dependent suppression of the antiproliferative activity of cephalostatin 1, OSW-1 and schweinfurthin A in the HCT-116 and HeLa cell lines ( Fig. 4a and Supplementary Fig. 7a,b) . Administration of 10 μM 25-OHC provided a nearly complete desensitization of HCT-116 cells treated with 250 nM of cephalostatin 1 or 10 nM OSW-1 (Fig. 4a )-doses that caused >75% growth inhibition when administered alone. 25-OHC also desensitized cells to schweinfurthin A, although to a lesser degree than for cephalostatin 1 and OSW-1 ( Supplementary Fig. 7b ). Notably, 25-OHC did not affect the antiproliferative activity of brefeldin A or taxol, demonstrating that 25-OHC does not nonspecifically desensitize cells to cytotoxic small molecules ( Supplementary Fig. 7a,b ).
In addition to OSBP and ORP4L, NPC1 (ref. 32) and Insig 33 are also cellular receptors of 25-OHC. NPC1 is involved in the egress of lipoprotein-derived cholesterol from lysosomes 34 . Insig is a chief regulator of SREBP-dependent cholesterol homeostasis, and 25-OHC exerts much of its ability to inhibit cholesterol biosynthesis through its binding to Insig 33 . However, we observed no change in the antiproliferative activity of cephalostatin 1, OSW-1 or schweinfurthin A in NPC1 −/− (M12) CHO cells compared to wild-type CHO cells, demonstrating that the activity of ORPphilins does not depend upon NPC1 ( Supplementary Fig. 8 ). In addition, we evaluated the antiproliferative activity of the natural products in the CHO-7 cell line, which is adapted to grow in lipoprotein-deficient media and is dependent on Insig-mediated cholesterol biosynthesis for survival 35 . Unlike that of 25-OHC, which is much more cytotoxic in the CHO-7 cell line, the antiproliferative activity of cephalostatin 1, OSW-1 and schweinfurthin A in CHO-7 cells was not enhanced in lipoprotein-deficient media. This result indicates that the ORPphilins do not affect cholesterol biosynthesis and are therefore not ligands for Insig (Fig. 4b ).
Mutant OSBP alleles desensitize cells to ORPphilins
To further support the idea that OSBP and ORP4L are targets of the ORPphilins, we mutated 15 OSBP residues both inside and outside the reported sterol binding region of the protein ( Supplementary Fig. 9 ) 36 . ORPphilin growth inhibition in HeLa cells expressing nearly equivalent amounts of either wild-type or mutant OSBP-Myc-His protein ( Supplementary Fig. 10a ) was determined (Table 1) . Two mutations in OSBP-Myc-His were revealed to confer ORPphilin resistance. Expression of OSBP M446W -Myc-His caused an 18-fold reduction in the antiproliferative activity of cephalostatin 1 at the GI 30 level compared to expression of wild-type OSBP-Myc-His (Table 1 , Supplementary Fig. 10c ). The GI 30 values are reported because they provide the clearest differential activities in the OSBP mutant overexpression experiments ( Supplementary Fig. 10c,d ). The same mutant caused a 3.9-fold reduction in the antiproliferative activity of OSW-1 and a 2.7-fold reduction in the activity of schweinfurthin A at the respective GI 30 levels (Table 1) . A second OSBP mutant, V582M, reduced the antiproliferative activity of cephalostatin 1 by 9.3-fold when compared to wild-type OSBP-Myc-His, yet this mutant did not affect the antiproliferative activity of OSW-1 or schweinfurthin A ( Table 1 , Supplementary Fig. 10c ). The antiproliferative activity of taxol was unaffected by expression of these two OSBP mutant proteins.
We then determined the binding affinity of cephalostatin 1, OSW-1 and schweinfurthin A to the OSBP M446W and OSBP V582M mutants using [ 3 H]25-OHC competition binding ( Table 1 , Supplementary Fig. 11 ). The binding affinity of 25-OHC for OSBP M446W was identical to that of the wild type. The OSBP V582M mutant had a slightly higher 25-OHC K D than the wild type. Within error limits, the binding affinities (K i ) of cephalostatin 1, OSW-1 and schweinfurthin A for these two OSBP mutants were unchanged compared to that of wildtype OSBP-Myc-His (Table 1, Supplementary Fig. 11 ). This suggests that these mutations provide resistance to the ORPphilins not by affecting compound binding but by altering the cellular function of OSBP. Based on the sequence alignment of OSBP and ORP4L, we then made mutations in ORP4L at positions equivalent to OSBP M446W and OSBP V582M . Unlike expression of the two aforementioned OSBP mutants, expression of ORP4L M550W and ORP4L V686M did not reduce cell sensitivity to the ORPphilins when compared to wild-type ORP4L-Myc-His ( Supplementary Fig. 10d ).
ORPphilins perturb the cellular localization of OSBP
OSBP translocates from a cytoplasmic distribution (Fig. 5a ) to the trans-Golgi network upon addition of 25-OHC to cells 37 . We treated HCT-116 cells with ORPphilins for short time periods (4 h) and monitored the effects on OSBP localization using immunofluorescence microscopy 38 . Much like 25-OHC 37, 38 (Fig. 5b) , schweinfurthin A caused OSBP to accumulate at perinuclear positions with a large degree of co-localization with the transGolgi marker p230 (Fig. 5c ). OSW-1 caused OSBP to localize to a perinuclear position that did not localize with p230 (Fig. 5d) . Instead, OSW-1 treatment caused the p230 marker to appear as small, dispersed vesicles, which indicates trans-Golgi dismemberment. As with OSW-1, cells treated with cephalostatin 1 also resulted in OSBP occupying a perinuclear position with little colocalization of the dispersed p230 marker (Fig. 5e) . However, unlike 25-OHC, OSW-1 or schweinfurthin A, cephalostatin 1 also caused OSBP to partially localize to the plasma membrane (Fig. 5e ). This effect was also observed with ritterazine B, although there appeared to be greater localization of OSBP and p230 with ritterazine B than with cephalostatin 1 (Supplementary Fig. 12a ). We also observed changes in OSBP localization upon treatment with ORPphilins in A549 cells (Supplementary Fig. 12b ). Treatment with schweinfurthin B resulted in perinuclear OSBP staining similar to that seen with 25-OHC, whereas cephalostatin 1 and OSW-1 in this cell line induced dispersal or vesiculation of OSBP.
Cephalostatin 1 and OSW-1 reduce OSBP levels
During our immunofluorescence studies, we noticed a lower fluorescent OSBP signal in cells treated for more than 8 h with either cephalostatin 1 or OSW-1. To determine if treatment with cephalostatin 1 or OSW-1 caused a reduction in the amount of OSBP in cells, we assessed OSBP concentrations in compound-treated HCT-116 cells by western blotting. Treatment with vehicle (DMSO) or 25-OHC (10 μM) did not affect OSBP levels (Fig. 6a) . However, treatment with cephalostatin 1 or OSW-1 induced a dramatic, time-dependent reduction in OSBP concentrations (Fig. 6a) . Treatment with 50 nM of cephalostatin 1 or 10 nM of OSW-1 caused an approximately 75% reduction in OSBP protein levels at 24 h in HCT-116 cells (Fig. 6a) , with a similar effect recorded in A549 cells (Supplementary Fig.  13a ). Notably, there was no effect on OSBP concentrations with schweinfurthin A (Fig. 6b) . Coadministration of 10 μM or 20 μM of 25-OHC, which does not affect OSBP levels (Fig.  6a,b) , significantly suppressed the reduction of OSBP levels induced by a 24-h treatment with 1 nM of OSW-1 (Fig. 6b) . This result further demonstrated the interference of 25-OHC with ORPphilin activity in cells, presumably by blocking ORPphilin binding to OSBP. Notably, administration of 5 μM schweinfurthin A with 10 nM of OSW-1 for 24 h completely suppressed the reduction of OSBP concentrations (Fig. 6b) . This result reveals that although OSW-1 and schweinfurthin A both bind and perturb OSBP in cells, they have considerably different effects on its activity.
To determine if cephalostatin 1 and OSW-1 induced proteasome-dependent degradation 39 of OSBP, we administered proteasome inhibitors MG-132 or lactacystin with cephalostatin 1 and OSW-1 (Fig. 6c) . MG-132 or lactacystin alone did not affect OSBP concentrations, but these inhibitors completely blocked the OSBP degradation induced by cephalostatin 1 and OSW-1 in HCT-116 cells (Fig. 6c) . Similar results were obtained in A549 cells (Supplementary Fig. 13a ).
ORPphilins affect sphingomyelin biosynthesis
Sphingomyelin is biosynthesized from ceramide at the Golgi 40 and is primarily transported from the ER to the Golgi by ceramide transport protein (CERT) 41 , and the transport activity of CERT is dependent on both OSBP and VAP-A [40] [41] [42] . In CHO-K1 cells, 25-OHC induces an increase in sphingomyelin biosynthesis in an OSBP-dependent fashion 43 . To determine whether the ORPphilins affect sphingomyelin synthesis, we performed pulse labeling with [ 3 H] serine in CHO-K1 and HCT-116 cells, then measured the amount of tritium incorporated into sphingomyelin and other lipids. As expected based on previous reports 43 , treatment of CHO-K1 cells with 25-OHC (5 μM) induced an approximately four-fold increase in the biosynthesis of sphingomyelin (Fig. 7) . Paralleling the effect of 25-OHC in CHO-K1 cells, low dose treatment (GI 10 ) with the ORPphilins induced an increase in sphingomyelin biosynthesis, similar to but not to the extent of 25-OHC (Fig. 7) . ORPphilin treatment did not significantly perturb the incorporation of radiolabel into phosphatidylethanolamine, a control lipid (Supplementary Fig. 14a ). In HCT-116 cells, treatment with a range of OSW-1 concentrations had no effect on ceramide labeling (Supplementary Fig. 14b ). This result is consistent with the ORPphilins altering the conversion of ceramide into sphingomyelin, a process that 25-OHC binding to OSBP is known to affect.
However, unlike 25-OHC, exposure of CHO-K1 cells to high doses (GI 90 ) of the ORPphilins caused a significant reduction in the biosynthesis of sphingomyelin (Fig. 7) . Contrasting with this observed effect, exposure of a GI 90 dose of 25-OHC (15 μM) caused a robust stimulation of sphingomyelin biosynthesis (Supplementary Fig. 14c ). Inhibition of sphingomyelin biosynthesis did not occur upon exposure of cells to taxol or the ER stressinducing small molecule thapsigargin, demonstrating that the ORPphilins do not inhibit sphingomyelin biosynthesis solely through the induction of cytotoxicity or ER stress. Suppression of CERT expression is reported to cause a significant reduction in basal sphingomyelin biosynthesis 40 . Therefore, we determined that the amount of CERT protein was not affected in HCT-116 or A549 cells treated with a GI 90 concentration of cephalostatin 1 or OSW-1 ( Supplementary Fig. 13a,b) , unlike the observed effect on the amounts of OSBP.
DISCUSSION
We identified OSBP and its closest paralog ORP4L as high-affinity receptors of cephalostatin 1, OSW-1, ritterazine B and schweinfurthin A that mediate the phenotypic effects of these compounds. Although there are indications that stellettin E has biological activities similar to those of these compounds, there is insufficient evidence to conclude that stellettin E is a member of the ORPphilins. Convergence of the ORPphilins on the same protein targets validates the indication of a shared mechanism of action provided by the similar pattern of growth inhibition in the NCI-60 cell line panel.
Our results clearly showed that the cytotoxic ORPphilins interact with OSBP and ORP4L, but OSBP and ORP4L were not known to be involved in cancer cell survival. This led us to obtain multiple lines of evidence showing that OSBP and ORP4L mediate the antiproliferative activities of the ORPphilins in cancer cell lines. Our results are consistent with the ability of the ORPphilins to induce an OSBP and ORP4L loss-of-function effect in cells: OSBP shRNA knockdown sensitizes cells to the ORPphilins, while OSBP and ORP4L overexpression confers ORPphilin resistance. However, these results alone did not rule out the possibility that OSBP and ORP4L were `decoy proteins', that is, high-affinity receptors that prevent the ORPphilins from reaching the actual efficacy targets that cause their antiproliferative effects. Therefore, we obtained three additional lines of evidence in support of OSBP and ORP4L as efficacy targets of ORPphilins. First, we measured a high correlation between ORPphilin affinity for OSBP and ORP4L and ORPphilin cytotoxic potency. Second, we showed that ORPphilin activity was suppressed by administration of nontoxic doses of 25-OHC, a high-affinity ligand of OSBP and ORP4L. Finally, we discovered two dominant ORPphilin-resistant alleles of OSBP. Interestingly, these mutants did not show altered binding to any of the compounds. The effects of these mutations on OSBP function will not be understood until a more thorough characterization of OSBP biochemistry is achieved. However, a possible explanation for the desensitization of cells overexpressing these OSBP mutants is that these mutations affect protein-protein interactions, and the interaction of OSBP and other proteins is involved in the antiproliferative activity of the ORPphilins. The thyroid hormone β-receptor provides a precedent for this possibility. Known mutants of this protein suppress ligand-induced transactivation by disrupting protein-protein interactions rather than by affecting ligand binding 44 . OSBP has several known interacting partners 16, 17 , and OSBP is reported to function as a sterol-sensing scaffolding protein that is capable of making multiprotein complexes in a ligand binding-dependent fashion 20, 21 . Therefore, it is reasonable to speculate that the activity of the ORPphilins was reliant on the interaction of OSBP with other proteins and that mutations altering OSBP protein-protein interactions modulated the activity of these compounds.
Taken as a whole, the aforementioned results strongly supported OSBP and ORP4L as efficacy targets. However, our finding that the ORPphilins caused an apparent loss of OSBP function at first appeared to be inconsistent with the lack of growth inhibition caused by OSBP shRNA knockdown. A possible cause for this discrepancy is that a complete or nearly complete ablation of OSBP expression is required for cell growth inhibition; the OSBP shRNA knockdown experiments reduced OSBP levels only by ~85%. In contrast, the ORPphilins, highlighting the power of small-molecule effectors, could inhibit total OSBP function in the cell. This is especially true for cephalostatin 1 and OSW-1, which have a dual means of disrupting OSBP function. Specifically, both compounds are high-affinity ligands (low nM K i ) of OSBP and induced OSBP degradation. A second explanation for this discrepancy is that depletion of both OSBP and ORP4L is required to phenocopy the effects of ORPphilin treatment. Lacking an effective ORP4L antibody, however, we could not perform a simultaneous knockdown of both proteins to test this.
A third possible explanation for the discrepancy is that the ORPphilins perturb the cellular functions of multiple members of the OSBP and ORP superfamily other than OSBP and ORP4L, and that the inhibition of these other family members contributes to the antiproliferative activity of the ORPphilins. This possibility would be more likely if a critical cellular function is performed redundantly by OSBP and many ORPs, which would mirror the situation in yeast. The yeast homologs of OSBP and the ORPs are called Osh proteins 16, 17 . Yeast have seven Osh proteins and can survive the loss of any six of these but not the loss of all seven 45 . Furthermore, the OSBP and ORP family has significant sequence homology in the lipid-binding domain 16, 17 , and most of its members have been shown to bind 25-OHC 46 . Given that the ORPphilins competed with 25-OHC for binding to OSBP and ORP4L, other OSBP and the ORPs could also bind these compounds. The significant desensitization achieved by administration of 25-OHC could be due to displacement of the ORPphilins from other ORPs beyond OSBP and ORP4L. Superfamily wide inhibition of OSBP and the ORPs, or inhibition of the subset of these proteins required for cell survival, would also explain the failure of genetic perturbation methods to uncover a role of the individual ORPs in cell proliferation, with a possible exception being the reported cytotoxicity upon inducible ORP9S expression 22 .
Excepting schweinfurthin A, 25-OHC and the ORPphilins had comparable binding affinities for OSBP and ORP4L, but the GI 50 values of the ORPphilins in human cancer cell lines are generally 1,000 times lower than for 25-OHC. This could be because ORPphilins bind at a different site from 25-OHC or because they have different effects on OSBP and ORP4L conformations. Additionally, 25-OHC is known to have many protein targets in cells, which could buffer the amount of 25-OHC reaching OSBP and ORP4L. Also, 25-OHC is rapidly esterified in cells, which could lower its affinity for OSBP and ORP4L and therefore reduce its cytotoxic effects 47 .
That the functions of OSBP and its paralogs, the ORPs, are not well understood is in part due to a lack of reagents capable of selectively altering the function of these proteins in cells. Although 25-OHC is often used to perturb OSBP and the ORPs in cells, its promiscuous interactions with NPC-1, Insig and other proteins complicates interpretation of these experiments. Our discovery that ORPphilins selectively target OSBP and ORP4L revealed new, high-affinity small-molecule probes of these proteins. Moreover, OSBP and ORP4L are implicated in atherosclerosis 16, 18, 19 , Alzheimer's disease 48 and breast cancer metastasis 49 . Thus, ORPphilins could be powerful reagents to study the role of OSBP and ORP4L in these processes.
Our discovery that the antiproliferative ORPphilins target OSBP and ORP4L poses the question of whether endogenous, highly cytotoxic OSBP and ORP4L ligands exist. If so, these ligands could be involved in lipotoxicity and human disease. Furthermore, as ORPphilins are selectively growth-inhibitory to tumor cells lacking p21, and schweinfurthin A is selective toward tumor cells lacking NF-1 (ref. 14) , to our knowledge our results provide the first indication that loss of these tumor suppressor proteins renders cells highly sensitive to perturbation of OSBP and ORP4L. Thus, our findings indicate that OSBP and ORP4L are new targets for achieving synthetic lethality with NF-1 and p21, which could result in tumor selective cancer therapeutics. We expect that the ORPphilins will be powerful reagents in helping uncover the function of OSBP and ORP4L, especially as the ORPphilins comprise three structurally diverse compounds, all targeting OSBP and ORP4L.
The ORPphilins will also be useful in studying the newly identified role of OSBP and ORP4L in cancer cell survival.
METHODS
Natural product compounds
Cephalostatin 1 (~2 mg) was supplied via total synthesis (carried out in the Shair laboratory 28 ). OSW-1 was obtained through isolation from nature and also through total synthesis in the Shair laboratory. OSW-1 analogs 6-10 were prepared as detailed in the Supplementary Methods section. Schweinfurthin A (~3 mg) and ritterazine B (0.2 mg) were obtained from the NCI. All compounds used were of analytical purity.
Antibodies
Polyclonal OSBP-specific (N terminus) rabbit antibodies (gift from H. Arai, University of Tokyo); polyclonal actin-specific rabbit antibodies (Sigma); monoclonal tubulin-specific (DSHB E7) mouse antibodies (Developmental Studies Hybridoma Bank); polyclonal cMyc-specific (N-262) rabbit antibodies (Santa Cruz Biotechnologies); monoclonal c-Mycspecific (9E10) mouse antibodies (Santa Cruz Biotechnologies); polyclonal COL4A3BP/ CERT-specific (ab72536) rabbit antibodies (Abcam); monoclonal p230-specific mouse antibodies (BD Biosciences).
Cell lines
HCT-116 wild type and HCT-116 p21 −/− cell lines were supplied by the Vogelstein laboratory (Johns Hopkins University). CHO-7 cells were a gift from M. Brown and J. Goldstein (University of Texas Southwestern Medical Center). M12 cells were a gift from D. Ory (Washington University, St. Louis). All other cell lines were purchased from ATCC.
Plasmids, vectors and OSBP shRNAs
The pcDNA 3.1/Myc-His vector and the pcDNA3.1/Myc-His lacZ control vector were purchased from Invitrogen. OSBP cDNA was purchased from Open Biosystems. ORP4L cDNA was cloned from HeLa total RNA extract using standard molecular biology techniques. The OSBP and ORP4L cDNAs were cloned into the pcDNA3.1/Myc-His vector (Invitrogen). OSBP M446W , OSBP V582M , ORP4L M550W and ORP4L V686M genetic mutants were prepared with the QuikChange II XL Site-directed Mutagenesis Kit (Stratagene) as instructed by the supplier. OSBP shRNAs in the pSIREN-RetroQ vector (BD Biosciences) were generously provided by G. Romeo (Joslin Diabetes Center).
Affinity chromatography experiment-iTRAQ
25 mg HeLa-S3 S100 lysate was pre-incubated with DMSO or 10 μM OSW-1 and then incubated overnight at 4 °C with 30 μl of packed OSW-1 affinity reagent (OAR) per pulldown. The resin was transferred to a Mobicol 1 ml column (Boca Scientific). The resin was washed extensively with buffer, and the bound protein was eluted via denaturation in NuPage LDS sample loading buffer under reducing conditions, alkylated with iodoacetamide and separated on a NuPage 4-12% Bis-Tris gradient gel (Invitrogen). Gel lanes were excised using a LEAP 2DiD robot and digested in-gel digested with trypsin (Tecan Freedom EVO 200), and the resulting eight samples per lane were labeled with iTRAQ reagent (AB/Sciex). Samples were mixed and analyzed using an Eksigent NanoLC 1D+ HPLC coupled to a Thermo LTQ-Orbitrap XL mass spectrometer operated in Pulsed-Q Dissociation mode. Peptide and protein identification and validation and quantitative data analysis were done via an automated workflow incorporating a forward and reverse version of IPIv3.55, Mascot v2.2 (Matrix Science) and Transproteomic pipeline v3.3sqall (Institute for Systems Biology) Spotfire DXP. Protein fold changes were derived as median peptide fold change, P values were calculated using a one-way t-test, and data were visualized for further analysis using Spotfire DXP. See Supplementary Methods for more details.
Cell viability assay
Cells were plated into 96-well plates in 75 μl of medium. After 24 h, a time-zero plate was produced by adding 25 μl of medium and 20 μl of CellTiter-Blue (Promega) to the wells and then incubating the plates at 37 °C for 90 min. Fluorescence (544 nm excitation; 590 nm emission) was detected using a SPECTRAmax Gemini XS to establish cell viability at time of dosing. Then, compounds were serially diluted in medium and delivered to the cells as 4× solutions in 25 μl of medium. At either 48 h or 72 h, CellTiter-Blue was added, and the fluorescence was recorded as described above. Growth relative to untreated cells was calculated, and this data was fitted to a four-parameter dose-response curve using GraphPad Prism 5.
Overexpression-viability assays with wild-type and mutant OSBP and ORP4L constructs were carried out by transfecting HeLa cells with the appropriate plasmids using Lipofectamine LTX with PLUS reagent (Invitrogen) as instructed, and after 8 h of transfection, the cells were replated for the cell viability assay, performed as described above. The amount of expression was evaluated by immunoblotting at the time of dosing.
[ 3 H]25-OHC charcoal-dextran binding assay
OSBP, OSBP M446W , OSBP V582M , ORP4L, ORP4L M550W , ORP4L V686M and lacZ were cloned into the pcDNA3.1 vector (Invitrogen), which encodes a C-terminal Myc-His tag. These vectors were transfected into HEK-293T cells using Lipofectamine2000 (Invitrogen), and 48 h after transfection, on-plate lysis of the transfected cells with M-Per with HALT and EDTA (ThermoScientific) reagent was performed, followed by ultracentrifugation at 100,000g. The S100 lysate was diluted to 0. 
Immunofluorescence microscopy
HCT-116 or A549 cells were plated on coverslips in six-well plates. After 72 h, the culture medium was removed and replaced with medium containing either compound or vehicle control. At the indicated time points, the cells were fixed for 10 min using 3.7% formaldehyde in PBS. The coverslips were washed with PBS and permeabilized for 5 min with 0.5% Triton X-100 in PBS. Following PBS washing, the coverslips were blocked for 30 min using Image-iT FX (Invitrogen), washed with PBS, then blocked for 30 min at room temperature with 1% BSA in PBS (BSA/PBS). The coverslips were then incubated overnight at 4 °C with a primary antibody solution in BSA/PBS. The coverslips were washed with BSA/PBS and incubated for 60 min at room temperature with Alexa Fluorconjugated secondary antibodies (Invitrogen) in BSA/PBS, including incubation with Hoechst 33258 in the final 30 min. The coverslips were then washed sequentially with BSA/ PBS, PBS and water and mounted on microscope slides using Aqua Poly/Mount (Polysciences). Imaging data was acquired using Zeiss LSM 510 META scanning confocal microscope.
Other methods
Any remaining experimental procedures are described in Supplementary Methods.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material. is blocked by addition of the proteasome inhibitors MG-132 or lactacystin. *P < 0.05 (n = 3), **P < 0.01 (n = 3), ***P< 0.001 (n = 3), ****P < 0.0001 (n = 3) relative to vehicle-treated cells; # P = 0.0006 (n = 3), ## P = 0.0196 (n = 3), ### P = 0.0025 (n = 3) (two-tailed Student's t-test). Uncut, full-gel image of a is shown in Supplementary  Figure 4 . Pulse-labeling of sphingomyelin with [ 3 H]serine in CHO-K1 cells. Cells were treated with vehicle or compound for 6 h, and in the last 2 h the cells were pulsed with 10 μCi [ 3 H]serine. Label incorporation into sphingomyelin was measured by scintillation counting after lipid isolation by thin layer chromatography. All data are mean ± s.d. from three individual experiments. *P < 0.05 (n = 3), **P < 0.01 (n = 3), ***P < 0.001 (n = 3), ****P < 0.0001 (n = 3) relative to vehicle-treated cells (two-tailed Student's t-test). Nat Chem Biol. Author manuscript; available in PMC 2011 September 7.
